With 37.96 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.41 whereas the lowest price it dropped to was $1.28. The 52-week range on LIXT shows that it touched its highest point at $3.00 and its lowest point at $0.64 during that stretch. Beta for the stock currently stands at 0.16.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LIXT was up-trending over the past week, with a rise of 159.31%, but this was up by 43.26% over a month. Three-month performance surged to 69.04% while six-month performance rose 1.00%. The stock lost -0.48% in the past year, while it has lost -14.77% so far this year.
Float and Shares Shorts:
At present, 2.68 million LIXT shares are outstanding with a float of 2.08 million shares on hand for trading. On 2025-06-13, short shares totaled 4456.0, which was 16.0 higher than short shares on 1747267200. In addition to Mr. Bastiaan van der Baan M.Sc. as the firm’s President, Chief Scientific Officer & Director, Mr. Robert Neal Weingarten serves as its CFO, VP & Secretary.
Institutional Ownership:
Through their ownership of 0.15843001 of LIXT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, LIXT reported revenue of $0.0 and operating income of -$706940.0. The EBITDA in the recently reported quarter was -$706499.0 and diluted EPS was -$0.29.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
